Last updated: July 31, 2026
Qbrelis is lisinopril oral solution, an FDA-approved liquid formulation for hypertension and adjunctive treatment of heart failure. The product contains lisinopril at 1 mg/mL and is primarily differentiated by administration convenience for pediatric patients, adults who cannot swallow tablets, and patients requiring dose measurement below available tablet strengths. Qbrelis does not have an active composition-of-matter patent, and its regulatory exclusivity has expired. Its commercial durability depends on formulation availability, prescribing preference, pharmacy distribution, and the limited number of competitors in the lisinopril oral-solution segment.
What is Qbrelis and how does it work?
Qbrelis contains lisinopril, an angiotensin-converting enzyme inhibitor. The product reduces angiotensin II formation, lowers aldosterone secretion, and decreases blood pressure.
| Attribute |
Qbrelis information |
| Active ingredient |
Lisinopril |
| Dosage form |
Oral solution |
| Strength |
1 mg/mL |
| Drug class |
ACE inhibitor |
| FDA application |
NDA 208510 |
| Initial FDA approval |
December 2016 |
| Primary indications |
Hypertension; adjunctive therapy for heart failure |
| Pediatric use |
Hypertension in patients aged 6 years and older |
| Administration |
Oral, measured liquid dose |
| U.S. prescription status |
Prescription drug |
| Reference product category |
Lisinopril oral products |
The liquid formulation avoids tablet splitting and supports weight-based or individualized dosing. The FDA label warns against use during pregnancy because ACE inhibitors can cause fetal injury or death. Other key risks include angioedema, hyperkalemia, renal impairment, hypotension, and adverse interactions with aliskiren, potassium supplements, potassium-sparing diuretics, and certain diabetes medicines.[1]
What clinical trials support Qbrelis approval?
Qbrelis did not establish a new pharmacologic mechanism or a new active ingredient. Its clinical basis is the established lisinopril evidence base, supplemented by product-specific pharmaceutical and pharmacokinetic data.
The FDA-approved labeling identifies pediatric antihypertensive evidence for lisinopril in children and adolescents aged 6 to 16 years. In the pivotal pediatric study described in the label, lisinopril produced dose-related reductions in blood pressure across low, intermediate, and high dose groups. The pediatric program supported use in hypertension but did not establish safety and efficacy in children younger than 6 years.[1]
What clinical trials are currently evaluating Qbrelis?
No major late-stage, registration-directed clinical development program for Qbrelis is publicly established. Qbrelis is a marketed formulation of an established generic active ingredient rather than an investigational therapy.
ClinicalTrials.gov contains studies involving lisinopril, ACE inhibitors, pediatric hypertension, heart failure, renal disease, and cardiovascular outcomes. Those studies should not automatically be treated as Qbrelis trials. Many evaluate lisinopril tablets, investigator-selected ACE inhibitors, or broader treatment protocols rather than the Qbrelis product.[2]
The commercially relevant evidence base therefore consists of:
- Historical lisinopril hypertension and heart-failure trials.
- Pediatric lisinopril data supporting use in patients aged 6 years and older.
- Product quality, stability, dose-uniformity, and manufacturing data supporting the oral solution.
- Postmarketing safety reports and routine pharmacovigilance.
What is the FDA regulatory status of Qbrelis?
Qbrelis was approved by the FDA under NDA 208510 in December 2016. The product is listed as a prescription oral solution containing 1 mg/mL lisinopril.[1]
The approval does not provide the level of regulatory differentiation associated with a new chemical entity. Qbrelis relies on a known active ingredient, established clinical pharmacology, and a differentiated dosage form.
What exclusivity did Qbrelis receive?
Any three-year new clinical investigation exclusivity associated with the NDA would have expired by 2019, assuming the standard Hatch-Waxman period ran from the 2016 approval date. Qbrelis has no remaining regulatory exclusivity that would ordinarily block an otherwise approvable competing product.
Qbrelis does not have biologic exclusivity and is not subject to the biosimilar pathway. A competing lisinopril oral solution would generally be evaluated through the abbreviated drug application framework if the product and reference-product requirements are satisfied.
What patents protect Qbrelis?
Qbrelis has no publicly identified active composition-of-matter patent because lisinopril was discovered and commercialized decades before the product’s approval.
| IP category |
Qbrelis position |
| Active ingredient patent |
Expired |
| New chemical entity exclusivity |
Expired |
| Product-specific formulation patent |
No active Orange Book-listed patent identified |
| Method-of-use patent |
No active Qbrelis-specific Orange Book-listed patent identified |
| Manufacturing patent |
Potentially relevant only if independently claimed and enforceable |
| Regulatory exclusivity |
Expired or no longer commercially blocking |
| Biosimilar exclusivity |
Not applicable |
The FDA Orange Book is the controlling source for patents listed against approved drug applications. Public Orange Book records should be checked by NDA number and product name because patent listings can change through delisting, expiration, or administrative updates.[3]
How strong is the Qbrelis patent estate?
The Qbrelis patent estate is weak as a blocking estate. The product’s main barrier is not patent exclusion. It is the practical difficulty of developing, manufacturing, packaging, validating, and distributing a stable, commercially viable lisinopril liquid.
Potential formulation barriers include:
- Chemical stability of lisinopril in aqueous solution.
- Control of pH and degradation products.
- Dose uniformity across the bottle life.
- Container-closure compatibility.
- Preservative and microbial-control strategy.
- Taste and patient acceptability.
- Accurate dosing with an oral syringe.
- Stability after opening and during pharmacy handling.
These factors can delay or discourage competition, but they do not create the same legal barrier as an enforceable patent.
What is the Orange Book status of Qbrelis?
Qbrelis is an FDA-approved prescription product, but the commercial significance of its Orange Book position is limited because the core lisinopril patents have expired and no durable Qbrelis-specific patent barrier is evident.
A competing manufacturer may pursue an abbreviated pathway where the FDA determines that the proposed oral solution can rely on the relevant reference product and satisfy requirements for pharmaceutical equivalence, bioequivalence, labeling, quality, and stability. A product-specific filing strategy would depend on the FDA’s reference-product designation and the proposed dosage-form characteristics.
Are generic manufacturers challenging Qbrelis?
No prominent public Paragraph IV litigation campaign against Qbrelis is established in the major public records through the available regulatory and litigation information.
That does not eliminate generic-entry risk. A challenger could enter through:
- An ANDA or other abbreviated pathway.
- A formulation-specific application.
- A licensed or contract-manufactured oral solution.
- A hospital or specialty-pharmacy channel strategy.
- A compounded or extemporaneous alternative, where legally permitted.
The absence of major litigation indicates that patent litigation is not currently the principal competitive issue. The more likely commercial threat is quiet entry by a manufacturer that can meet formulation and distribution requirements without triggering a high-value patent dispute.
What formulations compete with Qbrelis?
Qbrelis competes with lisinopril tablets, orally disintegrating or liquid alternatives where available, extemporaneously compounded lisinopril solutions, and other liquid ACE inhibitors.
| Product category |
Competitive position |
| Lisinopril tablets |
Lower cost and broad supply; less suitable for patients unable to swallow |
| Qbrelis oral solution |
Ready-to-use liquid; supports individualized dosing |
| Compounded lisinopril liquid |
Flexible but dependent on pharmacy capability and beyond-use dating |
| Enalapril oral solution |
Alternative ACE inhibitor liquid; different active ingredient and dosing |
| Captopril liquid or compounded formulation |
Alternative ACE inhibitor; shorter dosing interval |
| Losartan or other ARB liquids |
Alternative renin-angiotensin products; not pharmacologically identical |
Qbrelis has its strongest position where a ready-to-use liquid is clinically or operationally preferable to tablet manipulation. Its position is weaker in formularies focused almost entirely on acquisition cost.
What is the market opportunity for Qbrelis?
Qbrelis operates in a niche within the much larger lisinopril market. Lisinopril tablets are widely available from multiple generic manufacturers and are among the most frequently prescribed cardiovascular medicines in the United States. The oral-solution segment is much smaller but has fewer ready-to-use competitors.
Primary customer segments
The most relevant segments are:
- Pediatric hypertension.
- Adults with dysphagia.
- Patients using enteral feeding tubes.
- Patients requiring doses that are difficult to achieve with tablets.
- Long-term-care and institutional pharmacies.
- Specialty and hospital pharmacies.
- Caregivers who need a measured liquid dose.
The product’s value is greatest when tablet administration is impractical. The liquid presentation can reduce medication-administration complexity, but the price premium over generic tablets limits use in routine adult hypertension.
Commercial strengths
Qbrelis has four principal commercial strengths:
- It is ready to dispense and does not require pharmacy compounding.
- It supports precise liquid dosing.
- It addresses a recognized pediatric and dysphagia-use need.
- It benefits from the broad clinical familiarity of lisinopril.
Commercial weaknesses
The main weaknesses are:
- A small addressable market relative to lisinopril tablets.
- Low switching costs for prescribers and pharmacies.
- Limited protection from patents or exclusivity.
- Potential payer pressure.
- Competition from compounded formulations.
- Dependence on reliable supply of a niche dosage form.
- Low clinical differentiation from tablets once administration is feasible.
What is the Qbrelis revenue outlook?
Public company disclosures do not provide a dependable standalone revenue series for Qbrelis. The product is generally treated as a niche prescription asset rather than a separately reported blockbuster product.
A reasonable projection framework is scenario-based:
| Scenario |
Market condition |
Five-year commercial direction |
| Downside |
New ready-to-use generic solution, payer substitution, or supply disruption |
Revenue decline of roughly 20% to 40% |
| Base case |
Stable pediatric and dysphagia demand with limited direct competition |
Low-single-digit annual growth or flat revenue |
| Upside |
Increased pediatric liquid prescribing, broader institutional adoption, and reliable distribution |
Mid-single-digit to low-double-digit annual growth |
The base case is more likely than a rapid expansion scenario because the underlying lisinopril market is mature and heavily commoditized. Growth depends on increasing use of liquid dosage forms, not on expansion of the ACE-inhibitor class.
For valuation, the relevant metrics are prescription volume, net price after discounts, payer coverage, institutional contracts, direct competitors, gross margin, and supply continuity. A high list price does not necessarily translate into high net revenue in a market exposed to pharmacy benefit managers and generic substitution.
What generic launch risks exist for Qbrelis?
The most credible generic-launch scenario is a single competitor entering without extensive patent litigation. Such an entrant could pressure Qbrelis through pharmacy substitution, formulary positioning, and lower acquisition cost.
Likely launch scenarios
Scenario 1: No direct generic
Qbrelis maintains a niche position because the market is too small to attract multiple manufacturers. Revenue remains stable but growth is limited.
Scenario 2: One approved competitor
A single generic oral solution enters and captures price-sensitive accounts. Qbrelis retains pediatric, specialty, and prescriber-loyal segments.
Scenario 3: Multiple competitors
Several manufacturers enter after formulation know-how becomes accessible. Price erosion increases, and the product becomes a conventional generic liquid with limited brand premium.
Scenario 4: Compounding substitution
Pharmacies increasingly prepare lisinopril liquid or use alternative liquids. This would pressure demand without requiring FDA approval of a competing commercial product.
What patent litigation and settlements affect Qbrelis?
No material Qbrelis-specific patent litigation or Hatch-Waxman settlement is publicly established as a central commercial event. The absence of a significant settlement record is consistent with the product’s limited patent protection and modest market size.
The relevant legal risks are more likely to involve:
- Patent disputes over a competing liquid formulation.
- Trade-secret claims concerning manufacturing processes.
- Trademark disputes involving product names.
- Contract-manufacturing or supply agreements.
- State pharmacy-compounding rules.
- Product-liability claims involving dosing errors or contamination.
How does Qbrelis compare with competing liquid cardiovascular drugs?
| Factor |
Qbrelis |
Enalapril liquid |
Compounded ACE-inhibitor liquid |
| Active ingredient |
Lisinopril |
Enalapril |
Varies |
| FDA-approved ready-to-use product |
Yes |
Depends on product and market availability |
Usually no |
| Pediatric relevance |
High |
High |
Variable |
| Manufacturing consistency |
Commercially controlled |
Commercially controlled where approved |
Pharmacy-dependent |
| Patent barrier |
Low |
Product-specific |
Usually no commercial patent barrier |
| Cost position |
Higher than tablets |
Varies |
Varies |
| Main advantage |
Convenient once-daily liquid dosing |
Alternative ACE inhibitor |
Custom concentration and flexibility |
Qbrelis is strongest against tablet products when administration is the primary problem. It is less differentiated against another FDA-approved liquid ACE inhibitor with comparable dosing convenience and payer access.
What is the geographic coverage for Qbrelis?
The principal commercial market is the United States, where Qbrelis received FDA approval. Its regulatory and commercial value outside the U.S. depends on separate national approvals, local formulation requirements, pricing decisions, and distribution agreements. U.S. approval does not establish automatic rights in Europe, Canada, Japan, or other markets.
International expansion would require country-specific review of:
- Pediatric labeling.
- Oral-solution stability data.
- Excipient acceptability.
- Packaging and dosing-device standards.
- Local reference-product rules.
- Reimbursement and hospital procurement.
- Trademark availability.
Key Takeaways
- Qbrelis is a 1 mg/mL lisinopril oral solution approved by the FDA under NDA 208510 in December 2016.
- Its main value is administration convenience for pediatric patients, dysphagia patients, feeding-tube users, and patients requiring individualized doses.
- The product relies on established lisinopril clinical evidence rather than a novel clinical program.
- No major late-stage clinical-trial program specifically evaluating Qbrelis is publicly established.
- Regulatory exclusivity has expired, and no meaningful active Orange Book patent barrier is evident.
- Patent litigation is not the primary risk. Direct formulation competition, compounding, payer substitution, and supply disruption are more important.
- The market is niche, with limited volume but potentially higher value per prescription than lisinopril tablets.
- Base-case revenue is likely to remain stable or grow at a low-single-digit rate unless a direct generic oral solution enters.
- A single approved generic could cause material price and market-share pressure.
- Qbrelis has a stronger commercial position in pediatric and specialty channels than in routine adult hypertension.
FAQs
Is Qbrelis a generic drug?
Qbrelis contains the generic active ingredient lisinopril, but Qbrelis is an FDA-approved branded oral-solution product. Its commercial differentiation is the liquid dosage form.
Can Qbrelis be substituted with lisinopril tablets?
Clinically, lisinopril tablets contain the same active ingredient, but substitution requires consideration of dose, swallowing ability, feeding-tube administration, excipients, and state pharmacy rules.
Does Qbrelis have pediatric exclusivity?
Qbrelis is labeled for hypertension in patients aged 6 years and older. Any pediatric regulatory exclusivity associated with the approval period is no longer commercially active.
Is Qbrelis a biologic or biosimilar?
No. Qbrelis is a conventional small-molecule drug and is not subject to biosimilar approval rules.
What is the biggest investment risk for Qbrelis?
The primary risk is direct competition in the ready-to-use lisinopril oral-solution market. Because patent protection is limited, a qualifying competitor could reduce price and volume without a prolonged litigation cycle.
References
- U.S. Food and Drug Administration. (2016). Qbrelis (lisinopril) oral solution prescribing information. FDA.
- ClinicalTrials.gov. (n.d.). Studies involving lisinopril and pediatric hypertension. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
